In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.

@article{Pistiki2014InVA,
  title={In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth.},
  author={Aikaterini C Pistiki and I Despina Galani and Emmanouel Pyleris and Charalambos Barbatzas and Mark Pimentel and Evangelos J Giamarellos-Bourboulis},
  journal={International journal of antimicrobial agents},
  year={2014},
  volume={43 3},
  pages={236-41}
}
Rifaximin, a non-absorbable rifamycin derivative, has published clinical efficacy in the alleviation of symptoms in patients with irritable bowel syndrome (IBS). Small intestinal bacterial overgrowth (SIBO) is associated with the pathogenesis of IBS. This study describes for the first time the antimicrobial effect of rifaximin against SIBO micro-organisms from humans. Fluid was aspirated from the third part of the duodenum from 567 consecutive patients; quantitative cultures diagnosed SIBO in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 6 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome

Clinical and experimental gastroenterology • 2015
View 3 Excerpts
Highly Influenced

As Far as Travelers' Risk of Acquiring Resistant Intestinal Microbes Is Considered, No Antibiotics (Absorbable or Nonabsorbable) Are Safe

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…